CVR: 61094628
Secondary names: AXELLIA PHARMACEUTICALS ApS
Previous names: A/S DUMEX (DUMEX LTD.), DUMEX-ALPHARMA A/S, DUMEX-ALPHARMA ApS
Xellia Pharmaceuticals ApS has experienced significant financial volatility, with a concerning trend of declining profitability and fluctuating revenues over the past few years. In 2025, revenue decreased to 1.46 billion DKK, accompanied by a profit of 213.7 million DKK, a stark contrast to the previous year's profit of 828.9 million DKK on revenues of 1.6 billion DKK. The company faced substantial losses in 2023 and 2022, indicating ongoing challenges in maintaining profitability and a deteriorating equity position, which fell to 404.6 million DKK in 2025 from over 2 billion DKK in 2021. Despite being a notable player in the pharmaceutical raw materials sector, the significant equity erosion and recent profit fluctuations raise concerns about its financial stability and operational efficiency.
AI-generated summary
Selskabets formål er at drive fabrikation af og handel med medicinalvarer til human eller veterinær brug, finkemikalier, kosmetik, forskning og udvikling samt hermed beslægtet virksomhed enten direkte eller ved anbringelse af kapital i selskaber med ligende formål samt at virke som repræsentant eller alliancepartner for danske og udenlandske virksomheder inden for sådanne forretningsområder.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 1.5 mia. | 213.7 mio. | 2.8 mia. | 404.6 mio. | 453 | |
Compared to 25 companies in Fremstilling af farmaceutiske råvarer
Comparison is based on industry median values
5 properties
Upgrade to Pro to see addresses, building data and ownership details
Alexander Sebastian Benjamin Sproedt joined the board
Michael Kocher left the board
Companies in the same industry and area
CVR 44654482
CVR 45239128
CVR 35442723
CVR 35435212
CVR 39014149
companydata.dk